Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro

Cell Cycle

Volumn 11, Issue 14, 2012, Pages 2660-2671

  Wilk, Anna ^a   Urbanska, Katarzyna ^b   Grabacka, Maja ^c   Mullinax, Jennifer ^a   Marcinkiewicz, Cezary ^d   Impastato, David ^a   Estrada, John J ^a   Reiss, Krzysztof ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF AGRICULTURE IN KRAKOW   (Poland)

^d Temple University   (United States)

Author keywords

Energy metabolism; Fenofibrate; FoxO3A; Glioblastoma; PPAR

Indexed keywords

BIM PROTEIN; FENOFIBRATE; SERINE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR FKHRL1;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELLULAR DISTRIBUTION; CYTOTOXICITY; GLIOBLASTOMA; IN VITRO STUDY; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION;

EID: 84864378891     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21015     Document Type: Article

References (63)

1. Egerod FL, Nielsen HS, Iversen L, Thorup I, Storgaard T, Oleksiewicz MB. Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo. Biomarkers 2005; 10:295-309; PMID:16240504; http://dx.doi.org/10.1080/13547500500218682.
2. Grabacka M, Plonka PM, Urbanska K, Reiss K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via downregulation of Akt. Clin Cancer Res 2006; 12:3028-36; PMID:16707598; http://dx.doi.org/10.1158/1078-0432.CCR-05-2556.
3. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnés CM, Fannon M, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci USA 2008; 105:985-90; PMID:18199835; http://dx.doi.org/10.1073/pnas.0711281105.
4. Saidi SA, Holland CM, Charnock-Jones DS, Smith SK. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 2006; 5:13; PMID:16569247; http://dx.doi.org/10.1186/1476- 4598-5-13.
5. Gorin Y, Kim NH, Feliers D, Bhandari B, Choudhury GG, Abboud HE. Angiotensin II activates Akt/protein kinase B by an arachidonic acid/redox-dependent pathway and independent of phosphoinositide-3-kinase. FASEB J 2001; 15:1909-20; PMID:11532971; http://dx.doi.org/10.1096/fj.01-0165com.
6. Grabacka M, Reiss K. Anticancer Properties of PPARalpha-Effects on Cellular Metabolism and Inflammation. PPAR Res 2008; 2008:930705; PMID:18509489; http://dx.doi.org/10.1155/2008/930705.
7. Grabacka M, Pierzchalska M, Reiss K. Peroxisome Proliferator Activated Receptor α Ligands As Anticancer Drugs Targeting Mitochondrial Metabolism. Curr Pharm Biotechnol 2010; PMID:21133850.
8. Gardette V, Bongard V, Dallongeville J, Arveiler D, Bingham A, Ruidavets JB, et al. Ten-year all-cause mortality in presumably healthy subjects on lipid-lowering drugs (from the Prospective Epidemiological Study of Myocardial Infarction [PRIME] prospective cohort). Am J Cardiol 2009; 103:381-6; PMID:19166693; http://dx.doi.org/10.1016/j.amjcard.2008.09.092.
9. Shigeto T, Yokoyama Y, XinB, Mizunuma H. Peroxisome proliferator- activated receptoralpha and gamma ligands inhibit the growth of human ovarian cancer. Oncol Rep 2007; 18:833-40; PMID:17786343.
10. Yokoyama Y, Xin B, Shigeto T, Mizunuma H. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand and cisplatin enhances the inhibition of growth of human ovarian cancers. J Cancer Res Clin Oncol 2011; 137:1219-28; PMID:21681689; http://dx.doi.org/10.1007/s00432-011-0993-1.
11. Strakova N, Ehrmann J, Bartos J, Malikova J, Dolezel J, Kolar Z. Peroxisome proliferator-activated receptors (PPAR) agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors. Neoplasma 2005; 52:126-36; PMID:15800711.
12. Urbanska K, Pannizzo P, Grabacka M, Croul S, Del Valle L, Khalili K, et al. Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. Int J Cancer 2008; 123:1015-24; PMID:18546270; http://dx.doi.org/10.1002/ijc.23588.
13. Drukala J, Urbanska K, Wilk A, Grabacka M, Wybieralska E, Del Valle L, et al. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/ PPARalpha-mediated inhibition of glioma cell motility in vitro. Mol Cancer 2010; 9:159; PMID:20569465.
14. Grabacka M, Placha W, Plonka PM, Pajak S, Urbanska K, Laidler P, et al. Inhibition of melanoma metastases by fenofibrate. Arch Dermatol Res 2004; 296:54-8; PMID:15278363; http://dx.doi.org/10.1007/s00403-004-0479-y.
15. Araki H, Tamada Y, Imoto S, Dunmore B, Sanders D, Humphrey S, et al. Analysis of PPARalpha-dependent and PPARalpha-independent transcript regulation following fenofibrate treatment of human endothelial cells. Angiogenesis 2009; 12:221-9; PMID:19357976; http://dx.doi.org/10.1007/s10456-009-9142-8.
16. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 2007; 223:277-87; PMID:17658574; http://dx.doi.org/10.1016/j.taap.2007.06.003.
17. Zungu M, Felix R, Essop MF. Wy-14,643 and fenofibrate inhibit mitochondrial respiration in isolated rat cardiac mitochondria. Mitochondrion 2006; 6:315-22; PMID:17046337; http://dx.doi.org/10.1016/j.mito.2006.09.001.
18. Wybieralska E, Szpak K, Górecki A, Bonarek P, Miekus K, Drukała J, et al. Fenofibrate attenuates contact-stimulated cell motility and gap junctional coupling in DU-145 human prostate cancer cell populations. Oncol Rep 2011; 26:447-53; PMID:21617875.
19. Kops GJ, Dansen TB, Polderman PE, Saarloos I, Wirtz KW, Coffer PJ, et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002; 419:316-21; PMID:12239572; http://dx.doi.org/10.1038/ nature01036.
20. Hedrick SM. The cunning little vixen: Foxo and the cycle of life and death. Nat Immunol 2009; 10:1057-63; PMID:19701188; http://dx.doi.org/10.1038/ ni.1784.
21. Chiacchiera F, Simone C. The AMPK-FoxO3A axis as a target for cancer treatment. Cell Cycle 2010; 9:1091-6; PMID:20190568; http://dx.doi.org/10.4161/ cc.9.6.11035.
22. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001; 86:485-93; PMID:11410411.
23. Huang H, Tindall DJ. Dynamic FoxO transcription factors. J Cell Sci 2007; 120:2479-87; PMID:17646672; http://dx.doi.org/10.1242/jcs.001222.
24. Thépot S, Lainey E, Cluzeau T, Sébert M, Leroy C, Adès L, et al. Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia. Cell Cycle 2011; 10:2323-30; PMID:21654193; http://dx.doi.org/10.4161/ cc.10.14.16399.
25. Liu JW, Chandra D, Rudd MD, Butler AP, Pallotta V, Brown D, et al. Induction of prosurvival molecules by apoptotic stimuli: involvement of FOXO3a and ROS. Oncogene 2005; 24:2020-31; PMID:15674333; http://dx.doi.org/10.1038/sj. onc.1208385.
26. Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene 2008; 27:2312-9; PMID:18391973; http://dx.doi.org/10.1038/onc.2008.24.
27. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 2003; 162:613-22; PMID:12913110; http://dx.doi.org/10.1083/jcb.200303026.
28. Weber A, Paschen SA, Heger K, Wilfling F, Frankenberg T, Bauerschmitt H, et al. BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol 2007; 177:625-36; PMID:17517961; http://dx.doi.org/10.1083/jcb.200610148.
29. Nakada M, Nakada S, Demuth T, Tran NL, Hoelzinger DB, Berens ME. Molecular targets of glioma invasion. Cell Mol Life Sci 2007; 64:458-78; PMID:17260089; http://dx.doi.org/10.1007/s00018-007-6342-5.
30. Terzis AJ, Niclou SP, Rajcevic U, Danzeisen C, Bjerkvig R. Cell therapies for glioblastoma. Expert Opin Biol Ther 2006; 6:739-49; PMID:16856796; http://dx.doi.org/10.1517/14712598.6.8.739.
31. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352:997-1003; PMID:15758010; http://dx.doi.org/10.1056/NEJMoa043331.
32. Stupp R, Weber DC. The role of radio- and chemotherapy in glioblastoma. Onkologie 2005; 28:315-7; PMID:15933418; http://dx.doi.org/10.1159/000085575.
33. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006; 12:4899-907; PMID:16914578; http://dx.doi.org/10.1158/1078-0432.CCR-06-0773.
34. Trojan J, Cloix JF, Ardourel MY, Chatel M, Anthony DD. Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 2007; 145:795-811; PMID:17320297; http://dx.doi.org/10.1016/j.neuroscience.2007. 01.021.
35. Hau P, Jachimczak P, Schlingensiepen R, Schulmeyer F, Jauch T, Steinbrecher A, et al. Inhibition of TGFbeta2 with AP 12,009 in recurrent malignant gliomas: from preclinical to phase I/II studies. Oligonucleotides 2007; 17:201-12; PMID:17638524; http://dx.doi.org/10.1089/oli.2006.0053.
36. Warburg O. On the origin of cancer cells. Science 1956; 123:309-14; PMID:13298683; http://dx.doi.org/10.1126/science.123.3191.309.
37. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124:269-70; PMID:13351639.
38. Wolf A, Agnihotri S, Guha A. Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget 2010; 1:552-62; PMID:21317451.
39. Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, et al. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation? J Intern Med 2007; 262:184-98; PMID:17645586; http://dx.doi.org/10. 1111/j.1365-2796.2007.01825.x.
40. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 2002; 34:1249-57; PMID:12425323; http://dx.doi.org/10.1006/jmcc.2002.2061.
41. Randle PJ. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev 1998; 14:263-83; PMID:10095997; http://dx.doi.org/10.1002/(SICI)1099-0895(199812)14:4〈263:: AID-DMR233〉3.0.CO;2-C.
42. Wolfe RR. Metabolic interactions between glucose and fatty acids in humans. Am J Clin Nutr 1998; 67:519-26; PMID:9497163.
43. Reis RM, Könü-Lebleblicioglu D, Lopes JM, Kleihues P, Ohgaki H. Genetic profile of gliosarcomas. Am J Pathol 2000; 156:425-32; PMID:10666371; http://dx.doi.org/10.1016/S0002-9440(10)64746-3.
44. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration and invasion in glioblastoma multiforme cells. Oncotarget 2011; 2:833-49; PMID:22064833.
45. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002; 277:47928-37; PMID:12351634; http://dx.doi.org/10.1074/jbc.M207509200.
46. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999; 96:857-68; PMID:10102273; http://dx.doi.org/10.1016/S0092-8674(00) 80595-4.
47. Brunet A, Park J, Tran H, Hu LS, Hemmings BA, Greenberg ME. Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL1 (FOXO3a). Mol Cell Biol 2001; 21:952-65; PMID:11154281; http://dx.doi.org/10.1128/MCB.21.3.952-65.2001.
48. Skurk C, Maatz H, Kim HS, Yang J, Abid MR, Aird WC, et al. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem 2004; 279:1513-25; PMID:14551207; http://dx.doi.org/10.1074/jbc.M304736200.
49. Li Y, Wang Z, Kong D, Li R, Sarkar SH, Sarkar FH. Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem 2008; 283:27707-16; PMID:18687691; http://dx.doi.org/10.1074/ jbc.M802759200.
50. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, Yang JY, et al. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004; 117:225-37; PMID:15084260; http://dx.doi.org/10.1016/S0092-8674(04)00302-2.
51. Greer EL, Oskoui PR, Banko MR, Maniar JM, Gygi MP, Gygi SP, et al. The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 2007; 282:30107-19; PMID:17711846; http://dx.doi.org/10.1074/jbc.M705325200.
52. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, et al. Analysis of the phosphatidylinositol-3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 2003; 63:2742-6; PMID:12782577.
53. kip1. Nature 2000; 404:782-7; PMID:10783894; http://dx.doi.org/10.1038/35008115.
54. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, et al. Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002; 22:7842-52; PMID:12391153; http://dx.doi.org/10.1128/MCB.22.22.7842-52.2002.
55. Fei M, Zhao Y, Wang Y, Lu M, Cheng C, Huang X, et al. Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. Cancer Invest 2009; 27:52-9; PMID:19160093; http://dx.doi.org/10.1080/ 07357900802146204.
56. Dávila D, Torres-Aleman I. Neuronal death by oxidative stress involves activation of FOXO3 through a two-arm pathway that activates stress kinases and attenuates insulin-like growth factor I signaling. Mol Biol Cell 2008; 19:2014-25; PMID:18287535; http://dx.doi.org/10.1091/mbc.E07-08-0811.
57. De Bruyne E, Bos TJ, Schuit F, Van Valckenborgh E, Menu E, Thorrez L, et al. IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms. Blood 2010; 115:2430-40; PMID:20086250; http://dx.doi.org/10.1182/blood-2009-07-232801.
58. Wilk A, Urbanska K, Yang S, Wang JY, Amini S, Del Valle L, et al. Insulin-like growth factor-I-forkhead box O transcription factor 3a counteracts high glucose/tumor necrosis factorα-mediated neuronal damage: implications for human immunodeficiency virus encephalitis. J Neurosci Res 2011; 89:183-98; PMID:21162126; http://dx.doi.org/10.1002/jnr.22542.
59. Zheng WH, Kar S, Quirion R. Insulin-like growth factor-1-induced phosphorylation of the forkhead family transcription factor FKHRL1 is mediated by Akt kinase in PC12 cells. J Biol Chem 2000; 275:39152-8; PMID:10995739; http://dx.doi.org/10.1074/jbc.M002417200.
60. Cantó C, Auwerx J. Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev 2012; 64:166-87; PMID:22106091; http://dx.doi.org/10.1124/pr.110.003905.
61. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303:2011-5; PMID:14976264; http://dx.doi.org/10.1126/ science.1094637.
62. Troiano L, Ferraresi R, Lugli E, Nemes E, Roat E, Nasi M, et al. Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry. Nat Protoc 2007; 2:2719-27; PMID:18007607; http://dx.doi.org/10.1038/nprot.2007.405.
63. Trojanek J, Ho T, Del Valle L, Nowicki M, Wang JY, Lassak A, et al. Role of the insulin-like growth factor I/insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination. Mol Cell Biol 2003; 23:7510-24; PMID:14559999; http://dx.doi.org/10.1128/MCB.23.21.7510-24.2003.